source
- Novartis reports Phase 3 success for MS pill remibrutinib, beats Aubagio and shows no liver safety issuesNovartis announced that its BTK inhibitor remibrutinib met primary endpoints in two Phase 3 trials in patients with relapsing multiple sclerosis. The studies showed the drug reduced annualized rel…
- FDA releases draft guidance on evaluating drug behavior in patients with liver impairmentThe FDA has issued a draft guidance outlining how sponsors should design and analyze studies that assess the pharmacokinetics and pharmacodynamics of medicines in individuals with hepatic impairmen…